Trials / Completed
CompletedNCT01418430
Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- King's College Hospital NHS Trust · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety of the combination of CHOP plus daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHOP-daclizumab |
Timeline
- First posted
- 2011-08-17
- Last updated
- 2011-08-22
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01418430. Inclusion in this directory is not an endorsement.